Propath receives the Queen’s Award for Enterprise, in recognition of its contribution to the global life sciences sector.
The UK Prime Minister’s office has announced that Propath, a specialist in molecular pathology for biopharmaceutical research and development, has received the Queen’s Award for Enterprise in recognition of the company’s exceptional contribution to the Global Life Sciences sector.
As the UK’s most prestigious business accolade, the Queen’s Award is presented to those companies that demonstrate outstanding growth and achievement in business. Propath was selected to receive the award based on its contribution to the advancement of novel immunotherapies, and success in delivering specialist research services to the global biopharmaceutical sector.
Working with researchers across a wide range of therapeutic areas, including immuno-oncology and neuroscience, Propath’s success story spans across 40 years.
Drawing on its specialist expertise in spatial biology, molecular pathology and GLP/GCP compliant histopathology, Propath has become a trusted drug development partner of many of the world’s leading pharmaceutical and biotech companies across the globe.
Propath has invested consistently over many years in innovative technology and in hiring the most talented scientists, from PhD to graduate, with the aim of supporting Propath’s biopharmaceutical clients advance their novel therapeutics.
Dr Krish Soni, chief executive of Propath, commented, “It’s incredibly rewarding to be selected by our clients to work on their most promising and innovative drug development programmes. Over the years many of these research projects have progressed through clinical trials and are now improving the lives of patients globally – which is what matters and inspires the scientists that work at Propath. We’re tremendously proud and honoured to receive this prestigious award, which is a testament to the exceptional team we have at Propath”.